Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation

PHASE2TerminatedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

May 31, 2012

Primary Completion Date

July 23, 2014

Study Completion Date

July 23, 2014

Conditions
Carcinoma, Non-small Cell Lung
Interventions
DRUG

Dasatinib

Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression

Trial Locations (24)

112

Local Institution, Taipei

10065

Memorial Sloan Kettering Cancer Center, New York

Memorial Sloan Kettering Nassau, New York

14784

Local Institution, Barretos

33612

H. Lee Moffitt Cancer & Research Institute, Tampa

50924

Local Institution, Cologne

50931

Local Institution, Cologne

60488

Local Institution, Frankfurt

69120

Local Institution, Heidelberg

69126

Local Institution, Heidelberg

14784-400

Local Institution, Barretos

05403

Local Institution, S?o Paulo

01246-000

Local Institution, São Paulo

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

80-219

Local Institution, Gdansk

93-509

Local Institution, Lodz

02-781

Local Institution, Warsaw

CB2 2QQ

Local Institution, Cambridge

Local Institution, Cambridge

SW3 6JJ

Local Institution, London

M20 4BX

Local Institution, Manchester

NP20 2UB

Local Institution, Gwent

EH4 2XU

Local Institution, Edinburgh

SM2 5PT

Local Institution, Sutton

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT01514864 - Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation | Biotech Hunter | Biotech Hunter